Literature DB >> 22773801

Acute lymphoblastic leukemia.

Joseph C Alvarnas, Patrick A Brown, Patricia Aoun, Karen Kuhn Ballen, Naresh Bellam, William Blum, Michael W Boyer, Hetty E Carraway, Peter F Coccia, Steven E Coutre, Jennifer Cultrera, Lloyd E Damon, Daniel J DeAngelo, Dan Douer, Haydar Frangoul, Olga Frankfurt, Salil Goorha, Michael M Millenson, Susan O'Brien, Stephen H Petersdorf, Arati V Rao, Stephanie Terezakis, Geoffrey Uy, Meir Wetzler, Andrew D Zelenetz, Maoko Naganuma, Kristina M Gregory.   

Abstract

The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations. It is recommended that patients be treated at specialized centers with expertise in the management of ALL.

Entities:  

Mesh:

Year:  2012        PMID: 22773801     DOI: 10.6004/jnccn.2012.0089

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  21 in total

1.  Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization.

Authors:  Dorothea Evers; Jaap Jan Zwaginga; Janneke Tijmensen; Rutger A Middelburg; Masja de Haas; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Johanna G van der Bom
Journal:  Haematologica       Date:  2016-09-15       Impact factor: 9.941

2.  Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment.

Authors:  Julie A Wolfson; Joshua S Richman; Can-Lan Sun; Wendy Landier; Karen Leung; Eileen P Smith; Margaret O'Donnell; Smita Bhatia
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09-27       Impact factor: 4.254

Review 3.  Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Matt Stevenson; Abdullah Pandor; Jean Hamilton; John Stevens; Clare Rowntree; Marrissa Martyn-St James; Andrew Rawdin; Ruth Wong
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

4.  Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome.

Authors:  Julie Wolfson; Can-Lan Sun; Laura Wyatt; Wendy Stock; Smita Bhatia
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-02-16       Impact factor: 4.254

5.  Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.

Authors:  Nada Assaf; Jean El-Cheikh; Ali Bazarbachi; Ziad Salem; Chantal Farra; Zaher Chakhachiro; Samer Nassif; Ghazi Zaatari; Rami Mahfouz
Journal:  Mol Biol Rep       Date:  2019-01-30       Impact factor: 2.316

Review 6.  Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.

Authors:  Christopher S Hourigan; Philip McCarthy; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-27       Impact factor: 5.742

7.  Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Farhad Ravandi; Susan M O'Brien; Jorge E Cortes; Deborah M Thomas; Rebecca Garris; Stefan Faderl; Jan A Burger; Michael E Rytting; Alessandra Ferrajoli; William G Wierda; Srdan Verstovsek; Richard Champlin; Partow Kebriaei; Deborah A McCue; Xuelin Huang; Elias Jabbour; Guillermo Garcia-Manero; Zeev Estrov; Hagop M Kantarjian
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

Review 8.  The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.

Authors:  Victor D Fedorov; Vivek A Upadhyay; Amir T Fathi
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

9.  Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway.

Authors:  Yanchao Duan; Xin Dong; Jing Nie; Peng Li; Fei Lu; Daoxin Ma; Chunyan Ji
Journal:  Oncol Lett       Date:  2018-08-10       Impact factor: 2.967

Review 10.  Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.

Authors:  N K Gillis; J N Patel; F Innocenti
Journal:  Clin Pharmacol Ther       Date:  2013-10-17       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.